Forteo

This page shows the latest Forteo news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Amgen's osteoporosis hope romosozumab

Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak, ... Forteo is heading for patent expiry, so Radius'

Latest news

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck &Co's Lantus biosimilar. Also backs two biosimilar versions of Lilly’ s osteoporosis therapy Forteo. ... Forteo biosimilars. Meanwhile, the CHMP this month also issued positive opinions for two versions of Lilly's big-selling
Merck decision to drop odanacatib lifts UCB/Amgen

Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo
Amgen and UCB's romosozumab hits goals in male osteoporosis

Forteo is widely used in osteoporosis therapy and brought in sales of around $1.35bn last year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.
Amgen says romosozumab on track for 2016 filing

Amgen and UCB have previously reported data showing romosozumab was superior to Eli Lilly's parathyroid hormone-based Forteo (teriparatide), which requires daily dosing by injection. ... Forteo is widely used in osteoporosis therapy and brought in sales
Amgen buys back product rights from GSK

Forteo (teriparatide).

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Featured jobs

Associate Medical Director: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Scientific Team Lead: Competitive Salary

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Director – Head of Public Affairs: Neg

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Editorial Director – Medical Education: Neg

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Director Healthcare PR Communications: Salary TBC

Senior Account Executive – Medical Communications: Salary TBC

Account Director: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Experienced Editor, London, Medical Communications: Competitive package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Associate Medical Director: Highly Competitive

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Systematic Review Analyst - Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...